Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ABL1 |
Variant | G250E |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | ABL1 G250E lies within the protein kinase domain of the Abl1 protein (UniProt.org). G250E has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040), and results in increased catalytic efficiency (kcat/km) in an in vitro assay (PMID: 30684523), but has not been fully characterized and therefore, its effect on Abl1 protein function is unknown. |
Associated Drug Resistance | Y |
Category Variants Paths |
ABL1 mutant ABL1 G250E |
Transcript | NM_005157.6 |
gDNA | chr9:g.130862962G>A |
cDNA | c.749G>A |
Protein | p.G250E |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_005157.5 | chr9:g.130862962G>A | c.749G>A | p.G250E | RefSeq | GRCh38/hg38 |
NM_005157.6 | chr9:g.130862962G>A | c.749G>A | p.G250E | RefSeq | GRCh38/hg38 |
NM_005157 | chr9:g.130862962G>A | c.749G>A | p.G250E | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|